Breakthrough procedure could limit Parkinson’s tremors with ultrasound waves


26 Nov 2019407 Views

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Image: Ben Birchall/PA

Share on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Pin on PinterestShare on RedditEmail this to someone

Scientists are hopeful a new minimally invasive treatment for Parkinson’s disease could significantly relieve the effects of tremors.

Scientists believe they have developed a minimally invasive procedure that relieves tremors in patients with Parkinson’s disease. The approach applies pulses of focused ultrasound to the brain, according to a new study to be presented next week at the annual meeting of the Radiological Society of North America.

Scientists say it is safe and effective in reducing tremors and improving the quality of life of people with essential tremor (ET) or Parkinson’s disease (PD) tremor.

Previous treatment for reducing tremors in patients who have not responded to medical therapy include deep brain stimulation – a surgical procedure that involves implanting a small electrode in the brain connected to a pulse generator that is implanted in the chest like a pacemaker. A more recently available option is magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy.

This focuses beams of sound energy, which are used to heat and destroy a small part of a structure in the brain called the thalamus. The procedure provides relief to the opposite side of the body – meaning treatment to the right side relieves tremors on the left side of the body and vice versa.

Because it is minimally invasive, it reduces the risk of complications of bleeding and infections, said study lead author Dr Federico Bruno, from the department of biotechnological and applied clinical sciences at the University of L’Aquila, Italy.

Shorter hospitalisation

“Another advantage is the immediate effect this treatment provides, unlike deep brain stimulation, which requires a break-in period for the electrostimulation,” Bruno added.

“Additionally, treatment with MRgFUS requires shorter hospitalisation and is a fairly well-tolerated procedure even by more fragile patients.”

Researchers enrolled 39 participants with an average age of 64.5 years, who had disabling tremors that had not responded to treatment. The participants, 18 with ET and 21 with PD, had experienced symptoms for an average of more than a decade.

Scientists evaluated the patients for tremor severity and quality of life before MRgFUS thalamotomy, immediately after treatment and over the course of the following year. They found that 37 of 39 patients had substantial and immediate reduction of tremor.

The tremor reductions were sustained in follow-up evaluations, researchers said. Temporary side effects and complications – dysarthria, perioral paresthesias, limb weakness – occurred in seven patients after treatment, with resolution at the six-month follow-up in four patients.

– PA Media